Lithium News and Research

RSS

Mindfulness based cognitive therapy provides new hope for people with recurring depression

Research shows for the first time that a group-based psychological treatment, Mindfulness Based Cognitive Therapy (MBCT), could be a viable alternative to prescription drugs for people suffering from long-term depression.

30 Nov 2008

Cooling brain prevents cell death in young mice exposed to anesthesia

New research from Washington University School of Medicine in St. Louis suggests cooling the brain may prevent the death of nerve cells that has been observed in infant mice exposed to anesthesia.

17 Nov 2008

FDA seizes Heparin from Cincinnati manufacturer

As part of the U.S. Food and Drug Administration's ongoing efforts to ensure that heparin for patients remains safe, the government today seized 11 lots of heparin from Celsus Laboratories Inc. in Cincinnati, Ohio.

7 Nov 2008

Lithium carbonate to be tested for motor neurone disease

Victims of motor neurone disease (MND) will find hope from British research which has found that lithium carbonate, a cheap off-patent drug, may offer a treatment for the disease.

3 Nov 2008

Discovery of promising new chemotherapy target for a deadly form of leukemia

Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.

17 Sep 2008

Variation in Ankyrin 3 gene shows strong association with bipolar disorder

The largest genetic analysis of its kind to date for bipolar disorder has implicated machinery involved in the balance of sodium and calcium in brain cells. Researchers supported in part by the National Institute of Mental Health, part of the National Institutes of Health, found an association between the disorder and variation in two genes that make components of channels that manage the flow of the elements into and out of cells, including neurons.

17 Aug 2008

Lithium chloride slows development of inclusion body myositis

A new UC Irvine study finds that lithium chloride, a drug used to treat bipolar disorder, can slow the development of inclusion body myositis, a skeletal muscle disease that affects the elderly.

19 Mar 2008

New mouse model of bipolar disorder

Bipolar Disorder (BPD or manic-depressive illness) is one of the most serious of all mental disorders, affecting millions of individuals worldwide.

13 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

People with manic depression have a distinct chemical signature in their brains

People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.

5 Feb 2008

Lithium slows ALS progression

Daily doses of lithium, a drug used to treat bipolar disorder, have been found to delay progression of amyotrophic lateral sclerosis (ALS) in an Italian study of 44 people with the disease.

4 Feb 2008

Improved methods for decontamination of bioterrorism hazards

In October 2001, letters containing anthrax spores were mailed to several news media offices and two U.S. senators, killing five people and infecting 17 others.

30 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Stable sleep patterns and regular routines may improve outcomes in bipolar disorder

Bipolar disorder, commonly known as manic-depressive disorder, is highly influenced by the circadian system - the body's internal clock - and a specific kind of psychotherapy may help decrease irregularities in the circadian system that can trigger key symptoms of bipolar disorder, according to a study presented at the American College of Neuropsychopharmacology (ACNP) annual meeting.

10 Dec 2007

Lithium commonly used to treat bi-polar disorder increases lifespan in Nematode worms

Nematode worms treated with lithium show a 46 percent increase in lifespan, raising the tantalizing question of whether humans taking the mood affecting drug are also taking an anti-aging medication.

31 Oct 2007

Researchers discover drug-craving brain region in rats

Chilean researchers have identified a region of the brain - the insular cortex - that plays a role in drug craving in amphetamine-addicted rats, according to a report published in the 26 October issue of the journal Science, published by the American Association for the Advancement of Science (AAAS), the nonprofit science society.

25 Oct 2007

Breast cancer drug tamoxifen helps treat symptoms of bipolar disease

Government researchers in the United States have found that the breast cancer drug tamoxifen helped treat the manic symptoms of bipolar disease.

13 Sep 2007

Urgent need for better understanding of bipolar disease in children and adolescents

The number of visits to a doctor's office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH).

4 Sep 2007

Risperdal approved for psychiatric conditions in children and adolescents

The U.S. Food and Drug Administration has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.

24 Aug 2007

Antipsychotic drug Risperdal approved for use in children

The Food and Drug Administration (FDA) in the U.S. has given approval for the antipsychotic drug Risperdal to be used to treat schizophrenia and bipolar disorder in children and teenagers.

23 Aug 2007